本帖最后由 老马 于 2012-1-13 21:20 编辑
/ I! d! A# a% ]* N: S5 [9 V+ P Q; j; r i
爱必妥和阿瓦斯丁的比较
- V# A6 k- v# o' Z w% @: @ ]
1 T$ P# S! c* C: w$ j- I# a% Dhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
5 @- L+ V' i1 G
b6 r$ ?' W. |) ?7 v6 W* p* `
; g2 F% [! g; l7 p0 qhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/" X- h! E: O n2 F
==================================================5 ~8 L) {( _9 O% [* J
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
- O3 ]9 I3 j$ G( iPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.( T0 u% O! J# |# [0 u' B
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
/ o7 |1 y# r! A3 V4 e
|